Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tezampanel - Proniras

X
Drug Profile

Tezampanel - Proniras

Alternative Names: LY 293558; NGX 424; PRN-001-01

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Indiana University School of Medicine; Proniras Corporation; Raptor Pharmaceutical Corp
  • Class Analgesics; Antiepileptic drugs; Antimigraines; Antithrombotics; Drug withdrawal therapies; Isoquinolines; Tetrazoles
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Opioid-related disorders
  • No development reported Seizures
  • Discontinued Migraine; Neuromuscular disorders; Thrombosis

Most Recent Events

  • 01 Feb 2024 Proniras Corporation plans a phase I trial for Opioid related disorders (Parenteral)
  • 28 May 2022 No recent reports of development identified for preclinical development in Seizures in USA (Parenteral)
  • 17 Sep 2020 Proniras Corporation plans clinical trials for opioid addiction
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top